| Identification | Back Directory | [Name]
N,N-decane-1,10-diyl-bis-3-picolinium diiodide hydrate | [CAS]
525596-64-9 | [Synonyms]
bPiDI
bPiDl hydrate
N,N-decane-1,10-diyl-bis-3-picolinium diiodide hydrate
1,1′-(1,10-decanediyl)bis[3-methyl-pyridinium iodide (1:2) hydrate | [Molecular Formula]
C22H34IN2+ | [MDL Number]
MFCD21608520 | [MOL File]
525596-64-9.mol | [Molecular Weight]
453.43 |
| Hazard Information | Back Directory | [Uses]
bPiDl hydrate may be used to study nicotinic receptor-mediated signaling. | [Biochem/physiol Actions]
bPiDI is an α6β2-specific antagonist that inhibits nicotine-evoked and endogenous dopamine release from rat striatal slices (IC50 = 150 nM, Imax = 55%). bPiDI treatment decreases nicotine self-administration, and nicotine-induced locomotor activity in rats. |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|